Parkinson’s Foundation Launches New Program to Accelerate Clinical Trials
— PD Trial Navigator will help inform people of genetic-focused trials — NEW YORK and MIAMI, Aug. 19,…
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
Study Achieves Primary and Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight with Once-Daily VK2735 Dosing as…